Crazy for GI? Think again
The protection of Geographical Indication is not a guarantee that the artisan or producer will benefit; traders can corner the premium
A rather ridiculous gap
Clothing giant Gap’s trademark infringement notice to an NGO selling products made from recycled waste is a curious case
NCD battle starts now
The UN agreement on non-communicable diseases will get snagged on the issue of intellectual property rights for drugs
Obama takes first dip
The US becomes the first to join a global patents pool to make AIDS drugs cheaper but health workers are sceptical of the initiative
Access, yes. Sharing, no
The access and benefit-sharing protocol on biodiversity may do little to deter multinationals from grabbing the planet’s resources
Act of omission
Public institutions do not seek permission from the biodiversity authority before genetically manipulating crops
European Parliament rejects Anti-Counterfeiting Trade Agreement
Act makes it possible to seize and destroy even legitimately produced generic drugs exported from India to poor countries
Cipla's audacious move
Why generics maker Cipla has asked government to revoke Novartis patent on respiratory ailment drug
US keeps India out of Priority Foreign Country list of 'worst IP offenders'
US Trade Representative’s Special 301 Report keeps up pressure on India to fall in line with US’ interests
The natco-pfizer test
Natco’s demand for a voluntary licence from Pfizer will establish how well the compulsory licence process works in India
It’s still open season for bio-piracy
Rich nations block accord on benefit-sharing rules for the world’s genetic resources
Gunning for green tech
US continues to target India over its intellectual property regime, especially in pharma, green tech sectors
Choking access to drugs
Drug prices are likely to increase as rich countries and their pharma companies squeeze Indian generics out of the market. How can India’s …
Drug affordability test
Natco’s bid for a compulsory licence to manufacture a Bayer anti-cancer drug is a test of the law’s ‘reasonable price’ …
No climate for cleantech
Most of the clean energy innovations are with just six rich countries and hardly any technology is coming to developing nations
Patent hypocrisies of US
American business lobbies are spreading falsehoods about India’s patent policies—and glossing over their double standards
A lethal secrecy in trade deals
Why do democratic governments hide trade negotiations that have dire consequences for public services?
Pursuing a nationalist IPR policy
India has enough laws to protect its intellectual property rights. It is the implementation that is wanting
The pirates come ashore
German Pirate Party’s strong showing in the May elections is a sign that anti-IPR movements resonate with the people
Patent issues delaying Ebola cure
Canada's exclusive licensing rights of its Ebola patent to a US firm are holding up global development of a vaccine
What Durban did not discuss
IPRs are blocking access to mitigation and adaptation technologies. India offers a way out
New endosulfan ploy
Industry is sidestepping issues by pitching the proposed UN ban on endosulfan as the battle between generics and patented pesticides
Predatory EU pacts
EU is pushing India and Canada to sign free trade agreements that will hurt their generic drugs—and the outrage is global
WTO gives India a clean chit
Apex trade regulator finds nothing amiss in India's intellectual property laws after exhaustive review
A people’s festival to protest CBD conference
Non-profits to represent united resolve to protect the country’s natural wealth and bio-cultural heritage from powerful economic interests